Introduction
lacrimal drainage obstruction, ocular toxicity, toxicities, cancer, corneal disorders, ocular toxicities, retinal detachment
LACRIMAL DRAINAGE OBSTRUCTION, CANCER, CORNEAL DISORDERS, DYSFUNCTION, RETINAL DETACHMENT
Anti-cancer therapy has made remarkable progress in recent years with the emergence of molecular targeted agents, immune checkpoint inhibitors (ICIs), and antibodies (monoclonal antibodies, antibody–drug conjugates [ADCs], and bispecific antibodies). Ocular toxicities arising from cancer therapy are observed sporadically. Known frequent ocular toxicities include lacrimal drainage obstruction caused by S-1, corneal disorders caused by cytarabine and S-1, and retinal detachment caused by mitogen-activated protein kinase (MEK)-inhibitors, and other ocular toxicities caused by ICIs, fibroblast growth factor receptor (FGFR) inhibitors, anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibodies, and some ADCs [Since visual dysfunction is directly related to patients’ quality of life, careful management of ocular toxicities is necessary. However, ocular toxicity tends to be underestimated because it occurs at low frequency and is non-fatal. We investigated the detailed progression of ocular toxicities arising due to anti-cancer drugs in early phase clinical trials.